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MaBACKGROUND Clinical trials report improvements in function and perfusion with direct injection of bone marrow cells
into the hearts of patients with ischemic cardiomyopathy. Preclinical data suggest these cells improve vascular density,
which would be expected to decrease ﬁbrosis and inﬂammation.
OBJECTIVES The goal of this study was to test the hypothesis that bone marrow stem cells (CD34þ) will improve
histological measurements of vascularity, ﬁbrosis, and inﬂammation in human subjects undergoing left ventricular assist
device (LVAD) placement as a bridge to cardiac transplantation.
METHODS Subjects with ischemic cardiomyopathy who were scheduled for placement of an LVAD as a bridge to trans-
plantation underwent bone marrow aspiration the day before surgery; the bone marrow was processed into cell fractions
(bonemarrowmononuclear cells, CD34þ, and CD34–). At LVAD implantation, all fractions and a saline controlwere injected
epicardially into predetermined areas and each injection site marked. At the time of transplantation, injected areas were
collected. Data were analyzed by paired Student t test comparing the effect of cell fractions injected within each subject.
RESULTS Six subjects completed the study. There were no statistically signiﬁcant differences in complications with the
procedure versus control subjects. Histological analysis indicated that myocardium injected with CD34þ cells had
decreased density of endothelial cells compared to saline-injected myocardium. There were no signiﬁcant differences in
ﬁbrosis or inﬂammation between groups; however, density of activated ﬁbroblasts was decreased in both CD34þ and
CD34– injected areas.
CONCLUSIONS Tissue analysis does not support the hypothesis that bone marrowderived CD34þ cells promote
increased vascular tissue in humans with ischemic cardiomyopathy via direct injection. (J Am Coll Cardiol
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AB BR E V I A T I O N S
AND ACRONYM S
BMMC = bone marrow
mononuclear cells
FFC = fresh frozen plasma
LVAD = left ventricular
assist device
MI = myocardial infarction
PRBC = packed red blood cells
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1425More than a decade ago, studies in small animal
models showed that injection of bone marrow
derived stem cells improved cardiac remodeling
after myocardial infarction (MI) (1). Speciﬁcally, injec-
tion of either bone marrow stem cells (CD34þ) or bone
marrow mononuclear cells (BMMC) improved vascu-
larity, decreased scar burden, and resulted in improved
cardiac function compared to noninjected animals
(2,3). Follow-up studies using large animal models of
bone marrow cell injection after MI showed similar re-
sults (4,5).SEE PAGE 1435In vitro studies of human bone marrow cells pro-
duced tantalizing data that these ﬁndings could be
easily translated. Stem cells isolated from bone
marrow or circulated blood carrying the markers
CD34 and/or CD133 can differentiate into endothelial
cells and form vascular structures (6,7). Furthermore,
in vitro studies have shown that other bone marrow
cell components, including CD34þ cells and mesen-
chymal stem cells, can provide paracrine factors to
promote angiogenesis and cardiomyocyte cell sur-
vival; the same is observed when these cells are
transplanted into immune-deﬁcient rodents (8–11).
Clinical trials of bone marrow cell therapy in
humans with ischemic heart disease have not yiel-
ded as dramatic results as in animals. Direct injec-
tion of bone marrow cells into ischemic myocardium
has shown the most beneﬁt in a review of these
trials (12). Some subjects with chronic ischemic car-
diomyopathy undergoing intramyocardial injection
with BMMCs have improved function and perfusion
on noninvasive imaging studies compared to un-
treated subjects (13–18). However, other trials in
similar populations have failed to show a signiﬁcant
beneﬁt to this therapy (19). Furthermore, a trial in
subjects with nonischemic cardiomyopathy showed
similar beneﬁt (20), implying that the in vivo
mechanisms responsible for improvements in animal
models remain to be validated in humans.
We sought to analyze the potential mechanisms
by which bone marrow cells could improve cardiac
function in ischemic cardiomyopathy. We developed
a novel model in which tissue from humans with
severe ischemic heart disease could be analyzed
for structural changes after injection of bone mar-
rowderived cell fractions. Our studies revealed that
animal studies do not necessarily predict the effects
of cell therapy in humans, but do indicate potential
therapeutic beneﬁcial effects. Furthermore, these
studies shed light on the dynamic nature of repair even
in the presence of severe ischemic cardiomyopathy.METHODS
Twenty-six subjects with ischemic cardio-
myopathy scheduled for placement of a left
ventricular assist device (LVAD) as a bridge to
transplantation (BTT) were screened for the
trial (Figure 1). Inclusion criteria included age
>18 years, ischemic cardiomyopathy, and
need for LVAD implantations as a BTT.
Exclusion criteria included presence of an
intra-aortic balloon pump, emergent LVAD, and
inability of the subject to consent. Eight subjects
consented to the study. One subject withdrew and a
second was too unstable for injection. Of the 18 sub-
jects who refused consent or met exclusion criteria, 13
consented to safety data collection as controls.
The day before LVAD implantation, 15 to 20 ml of
marrow was collected from the iliac crest and trans-
ported to the Fred Hutchinson Cell Therapeutics fa-
cility. Marrow was processed into 3 fractions for
injection: 0.5  106 CD34þ cells, 1.0  106 CD34– cells,
and 1.0  106 BMMC cells, and placed in numbered
vials. An additional vial was loaded with 1 ml of Plas-
malyte (Baxter International Inc., Deerﬁeld, Illinois)
as a control. The contents of all vials were blinded to
the investigators (Online Figure 1). The doses of cells
correspond to the average cell number per injection
site reported in earlier clinical trials (Online Table 1).
Preoperatively, technetium single-photon emis-
sion computed tomography rest scans were reviewed
and areas of 50% to 75% perfusion identiﬁed for in-
jection. In the operating room, the contents of each
vial were drawn up into a sterile syringe ﬁtted with a
sterile 25-gauge needle. Pilot sheering studies indi-
cated minimal cell death (viability >98% by trypan
blue stain) with this diameter. Areas to be injected
were identiﬁed on the heart’s surface and a 1-cm
diameter marker sewn on. The cells for each fraction
and for saline were injected separately into the
area’s 4 quadrants. Thus, each area received 4 250-ml
injections of a single cell fraction or saline. After
injection, the LVAD implantation proceeded per
routine.
Case report forms were completed 24 h and 7
days after the LVAD implantation. Usage of blood
products (packed red blood cells [PRBCs]), fresh frozen
plasma (FFP), and platelets (PLT)] was recorded at
each time point. Chart notes, 12-lead electrocardio-
grams, and telemetry were reviewed to deﬁne epi-
sodes of ventricular tachycardia in the postoperative
period. Safety data were reviewed by the principal
investigator and the safety monitor after each subject
enrollment to assess for safety endpoints that would
preclude enrollment of additional subjects.
FIGURE 1 Study Enrollment
26 patients w/ IsCM scheduled
for BTT LVAD screened
8 patients consented
to study
18 Excluded
•   5 refused
•   6 required IABP
•   5 converted to DT LVAD
•   2 logistical issues
13 consented for
safety data collection
1 patient
withdrew
1 patient too unstable
in OR for injection
7 patients bone marrow
collected and processed
6 patients had cells
injected intra-operatively
Of the 18 originally excluded patients, 13 consented to safety data collection, serving as controls. BTT, bridge to transplantation;
DT, destination therapy; IABP, intra-aortic balloon pump; IsCM, ischemic cardiomyopathy; LVAD, left ventricular assist device;
OR, operating room.
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1426TISSUE HARVEST AND ANALYSIS. At the time of
transplantation, the explanted heart was obtained
and the markers identiﬁed. The area below each
marker was excised from the epicardial to endocardial
surface. After excision, this cube was cut into 4 sec-
tions to correspond to each injected region. Two
sections were processed for histology and 2 were
frozen in liquid nitrogen. One histological sample was
placed in sucrose formaldehyde and embedded in
parafﬁn. The second histological sample was ﬂash
frozen in OCT. For each endpoint, analysis was per-
formed on 5 50-micron step sections. Antibodies or
staining was used as follows for histological end-
points: Picrosirius Red for ﬁbrillar collagen, CD31
(1A10, Leica Microsystems Inc., Buffalo Grove, Illi-
nois) for endothelial cells, CD68 (M0876, Dako North
America, Inc., Carpinteria, California) for macro-
phages, alpha-smooth muscle actin (alpha-SMA)
(1A4, Dako) for activated ﬁbroblasts, and Ki-67
(M7240, Dako) for proliferating cells. Quantiﬁcation
of Picrosirius Red, CD31, and alpha-SMA was per-
formed by an automated image analysis system.
To quantify activated ﬁbroblast content, alpha-SMAþcells in blood vessel walls (smooth muscle cells) were
manually excluded. Quantiﬁcation of macrophage
density was performed by manual count of CD68þ
cells. Quantiﬁcation of blood vessels was performed
by manual count of circular CD31þ structures. Vessels
with 2 or fewer nuclei and no smooth muscle media
were counted as microvessels. Vessels with more
than 2 nuclei or containing a smooth muscle rich
media were counted as macrovessels. All analyses
were performed by blinded observers.
STATISTICAL ANALYSIS. To account for the effect
of injection on tissue structure, a saline-injected
segment was used as the control. Because each sub-
ject had their own control measurement within 1
of the 4 quadrants, we were able to examine the
difference of each treatment from control within
each subject. Outcome measurements were averaged
across samples for each subject, so each outcome
measure has 1 value per treatment for each subject.
The comparison of each treatment to the control is
a distinct biological question of interest. For each
outcome measure, we computed a 2-tailed paired
TABLE 1 Patient Characteristics
Patient Sex
Age
(yrs)
Injection to
Transplant
(Days)
Diabetes
Pre-LVAD
(Y/N)
Insulin
Pre-LVAD
(Y/N)
% CD34þ
in Bone
Marrow
% CD133þ
in CD34þ
Fraction
A1 M 70 177 N N 3.5 57.3
A2 M 57 241 Y Y 0.6* 46.9
A3 M 63 87 Y N 2.9 65.2
A4 M 60 374 Y Y 10.8 71.6
A5 F 54 42 Y Y 5.2 44.6
A6 M 60 53 Y N 3.2 75.6
All† M:83% 61  6 162  129 Y:83% Y:50% 4.4  3.5 60.2  13
*Insufﬁcient CD34þ cells (<0.5  106 ) could be isolated for injection. Value included in calculation of mean and
SD. †Values are mean  SD or %.
LVAD ¼ left ventricular assist device.
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1427Student t test to compare each treatment to control.
No adjustments for multiple comparisons were
applied. Analysis of safety endpoints was performed
using independent sample Student t tests and
Fisher exact test to compare patients in the study
group and the control group. Exploratory end-
points were examined using Pearson correlations
to compare results from CD34þ and CD34-depleted
treatments.
RESULTS
Six patients completed both bone marrow aspiration
and cell injection at the time of LVAD placement;
their clinical characteristics are shown in Table 1. Age
and incidence of diabetes was similar to previous
populations of patients with ischemic heart disease
eligible for cardiac transplantation. Eleven subjects
were on hydroxymethyl glutaryl coenzyme A reduc-
tase inhibitors. Content of CD34þ cells varied be-
tween subjects; however, all subjects had robust
representation of CD133þ cells in the CD34þ cell
fraction. One subject had insufﬁcient CD34þ cells for
injection, but received injection of BMMC fraction
and saline. Harvest of injected tissue occurred at time
of cardiac transplantation, and time between LVAD
placement and transplantation ranged between 47
and 374 days.
Comparison of safety endpoints between injected
patients and controls who underwent LVAD implan-
tation without injection showed no statistically sig-
niﬁcant differences in bleeding as quantiﬁed by
blood product use at 1 and 7 days postoperatively
(PRBC 4  2.2 U vs. 4.6  3.8 U; p ¼ 0.66; FFP 6  7.8 U
vs. 6  3.2 U; p > 0.9; PLT 1.3  1.2 vs. 2.3  2.4 6-pack
units; p ¼ 0.25 by independent samples Student
t test) (Online Figure 2). Furthermore, there were
no statistically signiﬁcant differences in the inci-
dence of ventricular arrhythmias in the ﬁrst week
post-LVAD between injected subjects and un-injected
controls (4 of 6 vs. 8 of 13; p > 0.9 by Fisher exact
test). There were no deaths or reoperations in either
group.
PRIMARY ENDPOINTS. To test the hypothesis that
injection of bone marrowderived CD34þ stem cells
would improve vascularity, we quantiﬁed the density
of endothelial cells as measured by CD31 staining
using automated image analysis. Surprisingly, the
areas injected with CD34þ cells had signiﬁcantly
fewer endothelial cells in comparison to saline in-
jected areas (0.0058  0.0032 vs. 0.013  0.0065 %
CD31þ area; n ¼ 5; p ¼ 0.02 by paired Student t test)
(Figure 2). Although not statistically signiﬁcant, there
was a trend toward a reduction in endothelial densityin regions injected with both the BMMC and CD34-
depleted cell fractions (BMMC 0.0068  0.0043 vs.
saline 0.011  0.0079, n ¼ 6; p ¼ 0.2; CD34-depleted
0.0085  0.0071 vs. saline 0.013  0.0065 %
CD31-positive area, n ¼ 5; p ¼ 0.2). Measurement
of microvascular density showed no statistically
signiﬁcant difference between saline and CD34þ cell
injected areas (55.7  4.7 vs. 59.8  16.7 vessels/mm2;
p ¼ 0.6).
Because stem cells may modulate cardiomyocyte
survival, we measured ﬁbrosis as a common endpoint
for a beneﬁcial effect of bone marrow cells on cardiac
structure. Overall, there was no statistically signiﬁ-
cant improvement in ﬁbrosis between tissue injected
with CD34þ, CD34-depleted, or BMMC compared to
saline-injected tissue (32.4  11.4, n ¼ 5; 31.7  15.8,
n ¼ 5; 33.3  16.1, n ¼ 6; 28.0  10.6, n ¼ 6, %
Picrosirius Redpositive area, respectively; p > 0.5
for each treatment compared to saline; Figure 3A).
Analysis of individual results showed a marked
variability in response of ﬁbrosis to cell therapy
(Figure 3B), although histology showed that signiﬁ-
cant ﬁbrosis remained in treated subjects indepen-
dent of response (Figures 3C to 3F).
SECONDARY ENDPOINTS. To determine if injection
of speciﬁc bone marrow cell fractions modulated
inﬂammation, activation of myoﬁbroblasts, or cell
proliferation, we quantiﬁed the density of CD68 (a
marker of macrophages), alpha-SMA (a marker of
activated ﬁbroblasts and vascular smooth muscle
cells), and Ki-67 (present in the nuclei of dividing
cells). There were no statistically signiﬁcant differ-
ences in macrophage density between saline-injected
tissues and tissues injected with any cell type (208.6
 36.3, n ¼ 5; 206.2  30.7, n ¼ 5; 201.3  50.2, n ¼ 6;
197.9  95.5, n ¼ 6; cells/mm2 for CD34þ, CD34-
depleted, BMMC, and saline, respectively; p $ 0.5
for each treatment comparison to saline) (Figure 4A).
FIGURE 2 Injection of CD34D Cells: No Increased Endothelial Density
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(A) Endothelial density quantiﬁed as percent positive area stained for CD31 (mean  SE);
*p ¼ 0.02 versus saline (B to E) Representative sections of CD31 immunohistochemistry
from a single subject. BMMC ¼ bone marrow mononuclear cells.
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1428On the other hand, there were signiﬁcantly fewer
activated myoﬁbroblasts (deﬁned as blood vessel
independent alpha-SMApositive) in tissues injected
with either CD34þ or CD34-depleted cells in com-
parison to saline-injected areas (CD34þ 4.6  1.2 vs.
saline 5.6  0.5, n ¼ 5; p ¼ 0.04; CD34-depleted 4.8
 0.9 vs. 5.6  0.5, n ¼ 5; p ¼ 0.014, % alpha-
SMA positive area) (Figure 4B).
Proliferating cells were observed in the interstitial
space in all segments as measured by Ki-67 positivity.
However, there were no differences in proliferating
cells detected in tissue injected with CD34þ stem
cells compared to saline-injected tissue (24.4  6.4
vs. 14.7  6.7 Ki-67 positive cells/mm2, n ¼ 5;
p ¼ 0.08) (Figures 4C and 4D). Ki-67 positivity was not
observed in nuclei contained within myoﬁbrils.To determine if bone marrow cells can trans-
differentiate into cardiac cell components, our pro-
tocol included incubation of a fraction of the BMMC
with Feridex, a solution of iron nanoparticles. Our
labeling protocol resulted in 82.5% iron positivity in
BMMC indicating that multiple cell populations were
labeled. The ﬁrst 2 subjects in the protocol under-
went injection of Feridex-labeled BMMC cell frac-
tions. However, soon after their enrollment, Feridex
was taken out of clinical production and further
subjects were unable to undergo cell labeling. Anal-
ysis of tissues for iron-labeled cells using Prussian
blue stain and matching with adjacent sections
with various immunohistochemistry cell phenotypes
showed that most iron-labeled cells were also
positive for the macrophage marker CD68 (Figures 5A
and 5B). No Prussian blue positive, CD31þ cells
were detected.
EXPLORATORY ENDPOINTS. Because our results
were contrary to the published literature and human
subjects have great genetic variability, we performed
several exploratory studies to determine if analysis
of individual patient results would be illuminating.
Analysis of the relationship of the time between cell
injection and tissue harvest revealed no differences
in our primary endpoints of endothelial density or
ﬁbrosis between subjects harvested early (<100
days) versus late (>170 days) after injection of cells.
To test whether cell effects were speciﬁc to CD34þ
stem cells, we correlated results from areas injected
with CD34þ and CD34-depleted areas. Intriguingly,
there was a tight correlation in the density of
macrophages, activated myoﬁbroblasts, and ﬁbrosis
between tissue injected with the stem cell versus
the nonstem cell fraction (Pearson correlation of
0.98, 0.90, 0.93, and p ¼ 0.004, 0.035, 0.023,
respectively) (Figures 5C to 5E).
DISCUSSION
In this unique trial we show the safety and feasibility
of direct injection of cell therapeutic products into
the hearts of human subjects with ischemic cardio-
myopathy undergoing LVAD implantation (Central
Illustration). Furthermore, we show that this strat-
egy can be used in a BTT population to determine
the mechanisms by which these cells alter cardiac
structure. Our data support the importance of these
mechanistic studies, as the effects of the cell frac-
tions in humans with advanced heart disease after
LVAD implantation were not as predicted from other
models. Speciﬁcally, injection of CD34þ stem cells
did not result in a statistically signiﬁcant increase
in vascularity in ischemic myocardium as deﬁned by
FIGURE 3 Injection of Bone MarrowDerived Cells: No Decreased Fibrosis
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(A) Cardiac ﬁbrosis quantiﬁed as percent positive Picrosirius Red area (mean  SE). (B) Changes in ﬁbrosis in individual subjects A1-A6 by
treatment group. Subject A5 is the only female subject. (C to F) Representative sections showing ﬁbrosis for subjects A3 and A5 in saline and
CD34þ-injected tissue. Abbreviations as in Figure 2.
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14292 separate measures: density of CD31þ endothelial
cells and number of manually counted blood vessels.
Furthermore, there were no statistically signiﬁcant
differences in ﬁbrosis or macrophage density in cell-
versus saline-injected segments. Although the study
lacked the power to detect small changes, the lack
of dramatic improvements in histological structure
makes it unlikely that these cell therapeutics would
result in meaningful functional improvements in
this patient population.
On the other hand, several of our results support
the hypothesis that cell therapy may modulate someelements of cardiac biology in subjects after LVAD
implantation and provide targets for future studies.
Areas injected with either CD34þ or CD34-depleted
cells had a signiﬁcantly decreased density of myoﬁ-
broblasts. Although this ﬁnding may represent a
Type 2 error, it was intriguing that the measurements
of myoﬁbroblasts, ﬁbrosis, and macrophage density
were highly correlated between areas injected with
CD34þ and CD34-depleted fractions, raising the hy-
pothesis that changes in myoﬁbroblast number are
insufﬁcient to alter ﬁbrosis and inﬂammation in this
population. Furthermore, our data showing the
FIGURE 4 Effects of Bone MarrowDerived Cell Injection on Beneﬁcial Remodeling
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saline); and (C) proliferating cells (Ki-67 positive; *p ¼ 0.08 versus saline). (D) Representative micrograph of Ki-67 immunohistochemistry in
CD34þ cell injected tissue.
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1430persistence of iron particles from labeled cells imply
that most injected cells eventually died, consistent
with animal studies (21). However, as only 2 subjects
received labeled cells it does not rule out the possi-
bility of persistence or transdifferentiation of small
numbers of injected cells.
A substantial literature in animal models and
ex vivo human cell culture has shown the ability
of bone marrowderived CD34þ stem cells to both
differentiate into vascular cells and promote vessel
formation via paracrine factors (2,22–24). Thus, use
of these cells to therapeutically increase perfusion
in patients with ischemic heart disease was rapidly
translated to clinical trials. These trials have targeted
different patient populations (post-MI, refractory
angina, and ischemic cardiomyopathy); used a
variety of cell fractions (BMMC, CD34þ, CD133þ,
and mesenchymal stem cells); and delivered cells
via intracoronary, direct epicardial injections, and
catheter-delivered endocardial injections. A meta-analysis and Cochrane Review of published trials
to date has shown modest improvements in ventric-
ular function with these cells at both early and late
time points after injection (12,25). Moreover, many
of these trials showed improvements in noninvasive
measurements of myocardial perfusion supporting
the hypothesis that bone marrow cell therapy directly
increases vascularity (26).
Patients with ischemic cardiomyopathy represent
a growing population and increasingly many of
these patients are undergoing LVAD placement (27).
There are reports of myocardial recovery after LVAD
implantation; however, these cases have been pre-
dominantly in subjects with idiopathic cardiomyop-
athy (28,29). It is presumed that in patients with
ischemic disease, both the presence of ﬁbrosis and
decreased myocardial perfusion contribute to a pro-
cess that is irreversible. We sought to determine
if recovery could be augmented in this population
via injection of cells to improve vascularity with
FIGURE 5 Effects of Bone MarrowDerived Cells and Cell Phenotype
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Abbreviations as in Figure 4.
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1431subsequent decrease in ﬁbrosis. Unfortunately, our
study failed to show dramatic improvements in
vascularity or decreases in ﬁbrosis on direct histologic
assessment.
There are several possibilities why our data may
be discordant with other preclinical and clinical
studies. First, this is the ﬁrst study to test the
angiogenic properties of bone marrow cells in unloa-
ded myocardium. Myocardial unloading by the LVAD
results in decreased oxygen use by the heart (30)
and other changes that may independently alter
the angiogenic properties of the cardiac tissue (31).
Furthermore, the aortic valve is closed during the
majority of cardiac cycles and ﬂow is nonpulsatile in
LVAD patients, which may modulate ﬂow-mediated
signals for angiogenesis (32,33). On the other hand,
in comparison to other clinical populations, the
consistent unloading of the LVAD provided a rela-
tively homogenous environment for the cells that
may obviate the need to control for changes in ﬁlling
pressures or new ischemic events in our population.Second, the quality of the cell product could have
contributed to the lack of effect. Several studies
have noted a correlation between patient character-
istics and angiogenic activity of stem cells. Stem cells
from older subjects or those with comorbid risk fac-
tors, such as hypertension and diabetes, may be less
robust at promoting angiogenesis by both trans-
differentiation and paracrine mechanisms (34). All
of our subjects were older, and 5 of our 6 subjects
had diabetes potentially impacting the angiogenic
capacity of the bone marrow cell fractions (35–37).
Because of the small amount of bone marrow
collected, we had insufﬁcient cells to test angiogenic
properties of the cell fractions. However, we did
conﬁrm signiﬁcant enrichment of CD133þ cells in
the CD34þ fractions in all subjects. Furthermore,
when analyzed as cells injected per volume of tissue,
our doses were close to other studies in patients
with similar clinical characteristics (Online Table 1),
if extrapolated to cells injected per cubic centimeter
(13,16). On the other hand, these doses are less than
CENTRAL ILLUSTRATION Cell Therapy in the Human Heart
Injection of bone marrow fractions into the heart does not increase vascularity but may decrease activated ﬁbroblasts and induce proliferation of resident
cardiac cells in human subjects with end-stage heart disease and left ventricular assist device support.
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1432doses in more recent studies focused on the anti-
anginal effect of cells in patients with similar risk
factors (38,39).
A ﬁnal explanation for the discrepancy between
our data and other models is the signiﬁcant difference
in the pathophysiology of advanced human cardio-
myopathy versus acute MI in both human subjects
and animal models. Unlike models in which a discrete
infarction is generated and cell therapeutics given
soon afterward, our human subjects had longstanding
neurohormonal activation with chronic remodeling
of even normally perfused areas of myocardium. This
ﬁbro-inﬂammatory milieu may alter tissue response
to cell therapy. Furthermore, as opposed to other
studies, all of our subjects had been exposed to
many years of medical therapy, which may alter the
response of their myocardium to cell therapies.
STUDY LIMITATIONS. Limitations of the study in-
clude: 1) left ventricle is unloaded during LVAD and
remodeling and effect of cell injection may not be
the same as in a non-unloaded heart; 2) small
numbers increase risk of both Type I and Type II
statistical errors; and 3) older age of donor cells may
have affected capacity for regeneration.CONCLUSIONS
Injection of bone marrowderived cells at the time
of LVAD implantation is safe and feasible and may
provide mechanistic insights into cell therapy. CD34þ
stem cells do not increase vascularity in the unloaded,
ischemic ventricle. Injection of cells may induce cellular
changes that are independent of the origin of the cell
therapeutic delivered. However, these data suggest that
preclinical studies of cardiovascular cell therapies are
insufﬁcient to predict results in human subjects with
chronic cardiomyopathy and LVADs. Similar mecha-
nistic studies should be performed before large-scale
clinical trials of other therapeutic cell products.
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PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: Fibrosis
and inﬂammation are common features of the myocar-
dium of patients with end-stage heart failure. Although
bone marrowderived stem cell therapy promotes
vascularity in preclinical models of acute myocardial
injury, this approach does not translate into histological
beneﬁt in patients with chronic ischemic heart disease
supported with left ventricular assist devices who are
awaiting cardiac transplantation.
TRANSLATIONAL OUTLOOK: Better mechanistic
models that more closely mimic chronic human heart
disease are needed to inform the design of clinical trials
of stem cell therapy.
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